



## OPEN ACCESS

EDITED AND REVIEWED BY  
Tang-Her Jaing,  
Chang Gung Children's Hospital, Taiwan














\*CORRESPONDENCE  
Fahad A. Bashiri  
✉ fbashiri@ksu.edu.sa

RECEIVED 28 August 2024  
ACCEPTED 27 September 2024  
PUBLISHED 22 October 2024

CITATION  
Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) Corrigendum: Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. *Front. Oncol.* 14:1487777. doi: 10.3389/fonc.2024.1487777

COPYRIGHT  
© 2024 Bashiri, Hundallah, Abukhaled, Alyahya, Al Futaisi, Alshowaeir, Al Tawari, Abdullah, Maaz, AlShamsi, Alshuaibi, Alotaibi and Aldhalaan. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations

Fahad A. Bashiri <sup>1\*</sup>, Khaled Hundallah <sup>2</sup>,  
Musaad Abukhaled <sup>3</sup>, Mossaed Mohammed Alyahya <sup>4</sup>,  
Amna Al Futaisi <sup>5</sup>, Daniah Alshowaeir <sup>6</sup>, Asmaa Al Tawari <sup>7</sup>,  
Shaker Abdullah <sup>8</sup>, Ata Ur Rehman Maaz <sup>9</sup>,  
Eman Taryam AlShamsi <sup>10</sup>, Walaa Alshuaibi <sup>11</sup>,  
Faisal Alotaibi <sup>12</sup> and Hesham Aldhalaan <sup>13</sup>

<sup>1</sup>Division of Pediatric Neurology, Department of Pediatrics, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, <sup>2</sup>Prince Sultan Military Medical City, Riyadh, Saudi Arabia, <sup>3</sup>Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, College of Medicine, Al Faisal University, Riyadh, Saudi Arabia, <sup>4</sup>Consultant of Neuro-oncology and Neuromuscular-neurology, Department of Oncology, King Faisal Specialist Hospital and Research Centre, Department of Neuroscience, King Faisal Specialist Hospital and Research Centre, Al Faisal University, Riyadh, Saudi Arabia, <sup>5</sup>Sultan Qaboos University, College of Medicine and Health Sciences, Muscat, Oman, <sup>6</sup>Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia, <sup>7</sup>Pediatric Neurology Unit, Pediatric Department, AlSabah Hospital, Ministry of Health, Kuwait City, Kuwait, <sup>8</sup>Department of Oncology, King Faisal Specialist Hospital & Research Center – Jeddah (KFSHRC-Jed), Jeddah, Saudi Arabia, <sup>9</sup>HemOnc Division, Department of Child Health, Sidra Medicine, Doha, Qatar, <sup>10</sup>Pediatric Hematology-Oncology Department, Al Jalila children's specialty Hospital, Dubai, United Arab Emirates, <sup>11</sup>Division of Medical Genetics, Department of Pediatrics, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia, <sup>12</sup>Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, <sup>13</sup>Department of Neurosciences, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

## KEYWORDS

children, Gulf Cooperation Council, management, neurofibromatosis type 1, referral

## A Corrigendum on

## Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations

By Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) *Front. Oncol.* 14:1323176. doi: 10.3389/fonc.2024.1323176

In the published article, there was an error in the FDA approval status of mirdametinib. A correction has been made to section **6.4 Treatment of NF1**, subsection **6.4.4 Targeted therapies**, paragraph 1. This sentence previously stated:

“Mirdametinib is a recently approved MEK inhibitor in July 2023 for the management of NF1-associated plexiform neurofibromas (105).”

The corrected sentence appears below:

“Other MEK inhibitors, mirdametinib, binimetinib, and trametinib are being investigated for the treatment of NF1-associated plexiform neurofibromas (104, 105).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.